shares of common stock at a price to the public of $0.42 per share
(the “Offering Shares”). In addition, we granted the Underwriters
an option to purchase, at the public offering price per share of
common stock, up to an additional 2,678,571 shares of common stock,
exercisable for 30 days from the date of the Underwriting Agreement
(the “Option Shares”). The Offering Shares and Option Shares
were registered pursuant to our registration statement
on Form S-3 (File No. 333-220461), and
a prospectus supplement thereto filed with the Securities
and Exchange Commission. The Underwriters acquired the
Offering Shares and the full amount of the Option Shares from us
with an underwriting discount of six percent (6%) and we also
agreed to reimburse them for customary fees and expenses.
After the underwriting discount of 6% and total offering
expenses of approximately $225,000 we received net proceeds of
approximately $7.9 million from the sale of the Offering Shares and
the Option Shares. We intend to use the proceeds from the
Offering for working capital requirements and general corporate
purposes. The sale of the Offering Shares and Option Shares
closed on July 24, 2020.
In connection with the Offering, the Company, its directors,
executive officers, and certain stockholders, subject to certain
exceptions, agreed to not sell or transfer any shares of common
stock or securities convertible into, or exchangeable or
exercisable for, the Company’s shares of common stock during a
period ending 90 days after the closing of the Offering. This
includes the Company’s use of the LPC Program and the ATM
Program.
Offering and private placement
transaction
On April 20, 2020, we entered into a securities purchase agreement
with certain institutional investors providing for the issuance and
sale of 15,000,000 shares of our common stock at a price of $0.20
per share, and in a concurrent private placement transaction, the
issuance of 11,250,000 warrants, ultimately consisting of 7,500,000
series A warrants and 3,750,000 series B warrants, to purchase up
to 11,250,000 shares of our common stock at an exercise price of
$0.30 per share, for aggregate gross proceeds of $3.0 million. The
securities purchase agreement contains customary representations,
warranties and covenants, in addition to granting the investors the
right to collectively participate in up to 50% of any future
offerings of securities by the Company on the same terms as other
investors, other than certain “exempt issuances” and “permitted
sales” as defined therein, until the first anniversary of the
closing date of the offering.
Each Warrant is exercisable six months from April 22, 2020, the
date of issuance, and has a term expiring five years after such
initial exercise date. The Warrants contain so-called
full-ratchet anti-dilution provisions which may be triggered
upon any future issuance by the Company of shares of its common
stock or common stock equivalents at a per share price below the
then-exercise price of the Warrant, subject to certain
exceptions; provided, however, that with respect to the
Series B warrants, the adjusted exercise price will not be less
than $0.26.
Total costs for the offering were approximately $290,000, including
the placement agent fee of six percent of the aggregate gross
proceeds, except, however, that a reduced fee was accepted with
respect to one investor.
Financial Results of
Operations
For the results of continuing operations discussed below, we
compare the results from operations for the three and six months
ended June 30, 2020 to the results from operations for the three
and six months ended June 30, 2019.
Three Months Ended June 30, 2020
Revenue from oxide plant lease.
We recorded revenue of $1.2 million and $2.0 million during
three-month periods ended June 30, 2020 and 2019, respectively,
related to the lease of our Velardeña oxide plant to a third party.
The decrease in revenue during 2020 is primarily related to a
reduction in the per tonne processing fees during the period
relating to the